Skip to content
Menu Close
Close button
Go back to News

PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics

A leader in the protein degradation space, Yale’s Craig Crews, is back with another biotech, Halda Therapeutics.

halda

Related News

See All News
Access Industries
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.